Noxopharm Ltd (ASX:NOX)’s drug Veyonda® has passed a milestone following the review of DARRT-2 safety data by the safety steering committee.
The DARRT-2 Phase 2 trial is assessing Noxopharm’s clinical drug candidate Veyonda® in combination with external beam radiotherapy for the treatment of prostate, breast and lung cancer.
Safe and well tolerated
The dosing data, from the second cohort of patients in the dose escalation part of the trial, indicated that the dose was safe and well tolerated.
This allows the trial to move to enrolling patients in a third cohort with an increased dose level.
The second dose cohort of patients in the trial was treated with 1200 milligrams of Veyonda.
With approval now given to progress the study, the third cohort of patients will receive a 1600-milligram dose of Veyonda.
Hungary adds trial site
The DARRT-2 trial has been authorised to proceed by major regulatory bodies in the US, Europe and Australia, and is now open for enrolment across three continents.
A new trial site in Hungary is now active and will soon begin enrolling patients.
The Hungarian site joins, among others, two prestigious hospitals in the US; the Beverly Hills Cancer Center in Los Angeles, and the renowned MD Anderson Cancer Center in Houston, one of the largest cancer hospitals in the world and consistently rated one of the best cancer treatment centres in the country.
Active enrolment is also underway in Sydney.
“The DARRT-2 trial continues to gain momentum as we have passed another significant milestone with a positive safety data review, and we are now recruiting patients in leading cancer hospitals across three continents,” Noxopharm CEO Dr Gisela Mautner said.
“We will keep the market updated as this trial progresses.”